NOTE 1 – DESCRIPTION OF BUSINESS

Ohr Pharmaceutical, Inc. (the “Company”) is a biotechnology company focused on the development of its previously acquired compounds, including two later stage lead products for the treatment of cancer cachexia and wet-AMD.

On June 3, 2013, the Company effected a 3:1 reverse stock split on its shares of common stock. Unless otherwise noted, impacted amounts and share information included in the financial statements and notes thereto have been retroactively adjusted for the stock split as if such stock split occurred on the first day of the first period presented. Certain amounts in the notes to the financial statements may be slightly different than previously reported due to rounding of fractional shares as a result of the reverse stock split.